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Background: Japanese encephalitis virus (JEV) infection leads to Japanese encephalitis (JE) in humans. JEV is
transmitted through mosquitoes and maintained in a zoonotic cycle. This cycle involves pigs as the major reservoir,
water birds as carriers and mosquitoes as vectors. JEV invasion into the central nervous system (CNS) may occur via
antipodal transport of virions or through the vascular endothelial cells. Microglial cells get activated in response to
pathogenic insults. JEV infection induces the innate immune response and triggers the production of type I
interferons. The signaling pathway of type I interferon production is regulated by a number of molecules. TRIM
proteins are known to regulate the expression of interferons; however, the involvement of TRIM genes and their
underlying mechanism during JEV infection are not known.
Methods: Human microglial cells (CHME3) were infected with JEV to understand the role of TRIM21 in JEV infection
and its effect on type I interferon (IFN-β) production. Cells were infected in presence and absence of exogenous
TRIM21 as well as after knocking down the TRIM21 mRNA. Levels of activated IRF3 expression were measured
through Western blot analyses of anti-p-IRF3 antibody, and IFN-β production was measured by using IFN-β
real-time PCR and luciferase activity analyses.
Results: JEV infection increased expression of TRIM21 in CHME3 cells. JEV induced an innate immune response by
increasing production of IFN-β via IRF3 activation and phosphorylation. Overexpression of TRIM21 resulted in
downregulation of p-IRF3 and IFN-β, while silencing led to increased production of p-IRF3 and IFN-β in JEV-infected
CHME3 cells.
Conclusion: This report demonstrates TRIM21 as a negative regulator of interferon-β (IFN-β) production mediated
by IRF-3 during JEV infection in human microglial cells.
Keywords: Japanese encephalitis virus, Viral encephalitis, Flavivirus, Antiviral mechanism, Immune evasion, TRIM
proteins, TRIM21, Type I interferons, IRF-3, Vector borne infectionBackground
Japanese encephalitis virus (JEV), a flavivirus with single-
stranded RNA, is the leading cause of viral encephalitis in
most of southeast Asian countries. JEV is transmitted
through mosquitoes and maintained in a zoonotic cycle.
This cycle involves pigs as the major reservoir/amplifying
host, water birds as carriers and mosquitoes as vectors [1].* Correspondence: sunitsingh2000@gmail.com
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stated.The estimated worldwide annual incidence of Japanese
encephalitis (JE) is about 45,000 human cases and 10,000
deaths [2]. JE leads to long-term neurological damage and
significant mortality among children. Approximately 25%
of encephalitis patients die, while about 50% of the survi-
vors develop permanent neurologic and/or psychiatric se-
quelae [1].
The flaviviruses are known to induce proinflammatory
response in CNS after infection.
A key step toward induction of innate immunity against
viral infections, including JEV, is the production of type Ial Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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recognition receptors (PRRs) such as Toll-like recep-
tors (TLRs) and RIG-I (retinoic acid-inducible gene 1)-
like receptors (RLRs) [3,4]. The engagement of these
(receptors) through pathogen molecular patterns can
lead to the production of various cytokines and che-
mokines and other proinflammatory factors. The key
regulators of the induction of type I IFNs during viral
infections are RIG-I and MDA5 (melanoma differentiation-
associated protein 5) [5-10]. These are known to inter-
act with MAVS (mitochondrial antiviral signaling
protein), which leads to downstream activation of vari-
ous kinases such as TBK1/IKKε (TANK-binding kinase
1/I kappa B Kinase-ε), which in turn lead to phosphor-
ylation and activation of various transcription factors
to induce IFN-β and IFN-α [11-13]. The production of
type I interferons is crucial for generating antiviral
response against viruses. Production of interferons is
mediated by various transcription factors such as inter-
feron regulatory factors (IRF). Among the IRF family
members, IRF-3 has been well documented to play a
role in expression of type I interferons in response to
viral infections. Phosphorylation of IRF-3 leads to acti-
vation, dimerization and nuclear translocation, ultim-
ately leading to the transcription and production of
IFN-β. IFN-β further initiates a cascade of signaling
events mediated by IRF-7 and IRF-5 resulting in the
production of IFN-γ and activation of various interferon-
stimulated genes (ISGs) [8,14].
The TRIM family (tripartite-motif family) of proteins
has been reported for their roles in regulating the innate
immune response to viral infections [15]. TRIM proteins
are structurally characterized by a RING domain, a
B-box domain and a coiled-coil domain [16,17]. Func-
tionally, most TRIMs are E3 ubiquitin ligases, where
RING domains have ubiquitin ligase activity, while the
b-Box domains have interacting motifs. TRIM proteins
have been reported for their roles in cellular processes
such as cell differentiation, transcriptional regulation,
signaling cascades and apoptosis [15,18,19]. Many TRIM
proteins play important roles in antiviral activities [20].
TRIM5 and TRIM22 are known to restrict HIV replica-
tion, while TRIM19 has been reported to restrict VSV
and herpes simplex virus (HSV) replication [21-24].
TRIM21 has been known to play a crucial role in regu-
lating type I interferon production, but its role during
viral infections is not well understood [25,26]. TRIM21
interacts and ubiquitinates IRF-3, IRF-7 and IRF-8 [27].
Due to such interactions, TRIM21 has been implicated
in regulating type I interferon signaling directly by
modulating the upstream transcription factors. TRIM21
is part of the RoSSA ribonucleoprotein, which includes a
single polypeptide and one of four small RNA molecules.
TRIM21 has been reported to recognize and degradeviruses in the cytoplasm by binding to antibody-coated
virions [28].
This is the first report showing the role of TRIM21 in
modulating the type I interferon response upon JEV in-
fection in human microglial cells. We have demon-
strated that induction of TRIM21 during JEV infection
is a compensatory mechanism to downregulate the type
I interferon production mediated by IRF-3. TRIM21
overexpression leads to downregulation of JEV-mediated
activation of IRF-3 and downstream IFN-β production,
whereas silencing of TRIM21 results in facilitation of
JEV-mediated activation of IRF-3 and upregulation of
IFN-β production. We thereby report the inhibitory role




The anti-p-IRF3 (Ser396) antibody (#4947S), anti-IRF3 anti-
body (#4302S), anti-IRF7 (#4920S) and anti-pIRF7 (#5184S)
antibodies were purchased from Cell Signaling Technology
(Danvers, MA, USA). Anti-β tubulin antibody (#Ab6046)
was from Abcam (Cambridge, MA, USA), while anti-
TRIM21 antibody (Ro52/SSA) (#sc-25351) was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Dulbecco’s Modified Eagle’s Medium (DMEM) (#12100–
046) was purchased from Gibco (Rockville, MD, USA).
Transfection reagents, Lipofectamine 2000 (#1168-019) and
GeneCellin (#GC1000) were from Invitrogen (Carlsbad,
CA, USA) and BioCellChallenge, respectively. SiRNA
against TRIM21 was purchased from Origene (Rockville,
MD, USA) along with Negative control scrambled RNA
(TRIM21 Trilencer-27 Human siRNA; #SR304594). IFN-
β-luciferase promoter was a kind gift from Dr. Adolfo
Garcia-Sastre (Mount Sinai School of Medicine, New
York City, NY, USA) while JEV (genotype 1 strain #
JaOAr) was gifted by Dr. Anirban Basu (NBRC, Manesar,
India). Real-time PCR primers were obtained from Bio-
serve (Hyderabad, India) and IDT (Belgium, Europe).
Cell culture
Human microglial cell line (CHME3 cells), porcine stable
kidney cell line (PS) (for plaque assay) and C6/36 cell line
(for viral propagation) were cultured in DMEM (Invitro-
gen) containing 10% heat-inactivated fetal bovine serum,
100 U penicillin, 100 g/ml streptomycin (#15140122; Invi-
trogen, Carlsbad, CA, USA) and L-glutamine. All cells
were grown in humidified atmosphere containing 5% CO2
and 95% air at 37°C (CHME3 and PS cells) and 28°C (C6/
36 cells).
JEV propagation, plaque assay and infection
JEV (genotype 1, JaOAr) was a kind gift from Dr. Anirban
Basu, NBRC, India. JEV was further propagated in C6/36
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in 75 cm2 (T-75) cell culture flasks and incubated for
7 days. Post infection, supernatant was collected and pre-
cipitated using a PEG viral precipitation kit (#ab102538;
Abcam, Cambridge, MA, USA). Plaque-forming units
(PFU) of the propagated virus were determined by plaque
assay by using porcine stable kidney cells (PS). Cells were
seeded at a density of 1.6 × 105 cells in six-well plates and
infected with JEV at different dilutions ranging from 10-3 −
10-10 for 2 h. Post infection, cells were washed with PBS,
and 2% low melting agarose overlay [containing 2X-
DMEM, 5% FBS and 1% antibiotic (penicillin-strepto-
mycin)] was added to each well. Plates were then incubated
at 37°C, 5% CO2, for 96 h. Viral plaques were fixed with
10% HCHO and stained with crystal violet in order to
count the number of plaques and determine the PFU for
JEV. Further infection experiments in this study were per-
formed using JEV at a multiplicity of infection (MOI) of 5
for 24 h, unless otherwise noted. For infection experi-
ments, CHME3 cells were infected with JEV at an MOI of
5 in incomplete DMEM alone for 3 h. Incomplete media
were replaced by complete growth media (DMEM with
10% FBS and antibiotics) 3 h later. Cells were harvested at
24 h post infection for RNA and/or protein isolation.
TRIM21 overexpression and knockdown
TRIM21 was cloned into the pcDNA3.1 vector. The prod-
uct was sequenced for confirmation and transformed into
DH5α competent cells. The plasmid was then isolated
using Qiagen maxi-prep kit (#12163; Qiagen, Hilden,
Germany) and observed on a 0.8% agarose gel for purity.
A truncated form of TRIM21 without the N-terminal
RING domain was also cloned into the pcDNA3.1 vector,
to be known as TRIM21 (ΔRING) in this study. TRIM21
protein is comprised of a RING domain from the 16th −
54th amino acid. Therefore, the TRIM21 (ΔRING) primers
were designed in such a way that the reverse primer was
similar to the wild-type TRIM21 clone, while the forward
primer was designed such as to start the polymerase reac-
tion from the 163rd nucleotide so that the RING domain
from the wild-type TRIM21 sequence was completely re-
moved. The PCR product was checked on an agarose gel
(Figure 1A). The PCR product was further eluted out of
agarose gel and digested using EcoR1 and HINDIII en-
zymes. Along with this insert, the pcDNA3.1 vector was
also digested using the same enzymes. Following digestion,
the vector and insert were ligated using T4 ligase at 15°C
overnight. The ligated product was transformed into E.
coli DH5α competent cells and spread on an LA agar plate
with ampicillin and incubated at 37°C for 15–16 h. The re-
sultant colonies were checked with PCR using TRIM21
(ΔRING) primers, and the positive colonies were further
inoculated in LB media to isolate the plasmid using the
Qiagen miniprep kit (#27104, Qiagen, Hilden, Germany)according to manufacturer’s protocol. The resultant plas-
mid was validated by sequencing and used for transfection
studies. To validate the expression of truncated TRIM21,
CHME3 cells were transfected with TRIM21 (WT) and
TRIM21 (ΔRING) for 48 h. Lysates were resolved on SDS-
PAGE and probed with for anti-TRIM21 antibody by
Western blot. For overexpression, 1 day prior to transfec-
tion, CHME3 cells were seeded in 25 cm2 cell culture flasks
at 70% confluency. Cells were transfected with 4 μg of ei-
ther TRIM21 or TRIM21 (ΔRING) plasmid per 600,000
cells using GeneCellin transfection reagent in 4 ml trans-
fection media (DMEM with 10% FBS). Cells were replen-
ished with complete growth media (DMEM+ 10% FBS +
antibiotics) after 8 h of transfection and incubated for 48 h.
In cases of infection experiments, 24 h post transfection,
cells were infected with JEV at MOI 5 and lysed 24 h post
infection. In case of silencing of TRIM21, siRNA against
TRIM21 was transfected to CHME3 cells in six-well plates
(1.5 × 105 cells per well) using Lipofectamine 2000 transfec-
tion reagent. Cells were either non-transfected (control),
transfected with scrambled RNA provided in the siRNA kit
(negative control) or transfected with siRNA duplex for
48 h. Cells were infected 24 h post transfection in the ex-
periments wherever required.
Western blotting
Cells were transfected with TRIM21 plasmid for overex-
pression studies and siRNA for silencing studies as de-
scribed above. After 48 h of transfection, cells were lysed
using RIPA (150 mM NaCl, 50 mM Tris–HCl, pH 7.5,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) buffer
containing 1 μM PMSF and 1X protease inhibitor cock-
tail, ProteCEASE-50 (#427P; G-Biosciences, St. Louis,
MO, USA). Protein was quantified using Bradford assay
[29]. Lysates were resolved on SDS-PAGE and Western
blotted using the desired antibodies against p-IRF3
(1:3,000 dilution), IRF3 (1:3,000), TRIM21 (1:5,000), p-
IRF7 (1:3,000) and IRF7 (1:3,000). Optical densities for
p-IRF3, p-IRF7 and TRIM21 from visualized Western
blots were normalized to their respective loading con-
trols (IRF3/IRF7/β-tubulin) and averaged from three in-
dependent experiments.
Real-time PCR
For RNA isolation, cells were harvested and total RNA
isolated using Qiagen RNeasy kit (#74106; Qiagen, Hilden,
Germany). Synthesis of cDNA was performed using
Superscript II reverse transcriptase system (#11904-018;
Invitrogen, Carlsbad, CA, USA) according to manufac-
turer’s protocol using 2,000 ng RNA. Thermal cycles of
cDNA synthesis using random hexamers were as follows:
65°C (5 min); 25°C (10 min); 42°C (50 min); 70°C
(10 min); followed by treatment with RNase H for 20 min
at 37°C. For amplification, 100 ng cDNA was used as a
Table 1 List of primers
Gene name Primer sequence (5′-3′)
TRIM21 Fwd: 5′ AGAGAGACTTCACCTGTTCTGT 3′
Rev: 5′ TCAGTTCCCCTAATGCCACCT 3′
TRIM21 (ΔRING) Fwd: 5′ TACGAATTCCGGCAGCGCTTTCTGCTC 3′
Rev: 5′ GCCAAGCTTATAGTCAGTGGATCCTTG 3′
IFN-β1 Fwd: 5′ GCTCTCCTGTTGTGCTTCTCCAC 3′
Rev: 5′ CAATAGTCTCATTCCAGCCAGTGC 3′
β-Actin Fwd: 5′ GTCTGCCTTGGTAGTGGATAATG 3′
Rev: 5′ TCGAGGACGCCCTATCATGG 3′
Figure 1 TRIM21 attenuates the JEV mediated upregulation of the p-IRF3 level and IFN-β level in human microglial cells. (A) PCR
amplification of TRIM21 and TRIM21 (ΔRING) primers was carried out and the product run on 1% agarose gel (upper panel). Expression of
wild-type TRIM21 as well as the TRIM21 (ΔRING) domain was confirmed by Western blotting (lower panel). (B) CHME3 cells were transfected with
4 μg of TRIM21 plasmid or TRIM21 (ΔRING) for 48 h. Cell lysates were resolved on SDS-PAGE and probed with anti-TRIM21, anti-IRF-3 and anti-β-
tubulin antibodies by Western blotting. Representative image is shown. (C) Cells transfected with TRIM21 or TRIM21 (ΔRING) were infected with
JEV, and total RNA was isolated post 48 h of transfection. Real-time PCR for IFN-β1 was performed, and an average of three independent sets of
experiments is plotted and shown. (D) Luciferase assay for IFN-β for cells transfected with TRIM21 or TRIM21 (ΔRING) and infected with JEV along
with respective controls was performed. Luciferase activity normalized against β-gal activity was averaged and plotted (*p <0.05, **p < 0.01,
***p < 0.001 from control).
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Supermix (#4367659; Applied Biosystems, Warrington,
UK). Sequences of all the primers used for various genes
in this study are mentioned in Table 1.
IFN-β luciferase assay
CHME3 cells were seeded at a density of 65,000 cells
per well in 12-well Plates 1 day prior to transfection.
Cells were transfected with IFN-β-Luc reporter plasmid
(1 μg/ml) and β-gal (350 ng/ml) in 1 ml of transfection
media (DMEM+ 10% FBS). In case of TRIM21 overex-
pression, 1 μg/ml TRIM21 plasmid was co-transfected,
while in case of knockdown, 10nM siRNA for TRIM21
was co-transfected. In conditions where infection was
required, cells were infected with JEV (MOI 5) 24 h post
transfection. After 48 h of transfection (24 h after
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formed using the Luciferase assay kit (#E4030; Promega,
Madison, WI, USA) according to the manufacturer’s
protocol. Cells were lysed in 150 μl 1X lysis buffer and
centrifuged at 12,000 g for 3 min, and the supernatant
was used for luminescence measurement using the Lu-
ciferase assay reagent. Normalization was done by per-
forming a β-galactosidase assay using the β-galactosidase
kit (#E2000; Promega, Madison, WI, USA). For this
assay, 50 μl of the lysate supernatant was incubated with
50 μl 2X assay buffer at 37°C for 30 min, and the result-
ing yellow color was read at 420 nm. β-gal activity (in
milliunits) in each of the lysates was obtained using a
standard curve, and IFN-β luciferase activity was nor-
malized (against β-gal activity), averaged and plotted for
three independent sets of experiments.
Statistical analysis
Data are presented as mean ± standard error. Statistical
significance was calculated by using one-way ANOVA
and/or Student’s t-test. The Tukey-Kramer multiple
comparisons post hoc test was used to determine P-
values.
Results
JEV induces IFN-β production in a time-dependent
manner in human microglial cells
In order to verify the innate immune response being
generated during JEV infection, we studied the level of
IFN-β mRNA as well as IFN-β luciferase activity inFigure 2 JEV infection leads to a time-dependent increase in IFN-β lu
transfected with IFN-β-luciferase promoter plasmid and β-gal promoter pla
activity was measured, normalized and averaged for three independent ex
and total RNA isolated and quantified by real-time PCR for IFN-β1 levels. Fo
experiments was averaged and plotted (*p < 0.05, **p < 0.01, ***p < 0.001 frmicroglial cells. Human microglial cells (CHME3) were
infected with JEV at an MOI of 5 and harvested at vari-
ous time intervals of 6, 12, 24 and 36 h. Infected cells
were lysed using the reporter lysis buffer for the IFN-β-
luciferase assay. IFN-β luciferase activity increased with
JEV infection in a time-dependent manner until 24 h
(Figure 2A). Since the maximal increase in IFN-β levels
was observed at 24 h, all further experiments were per-
formed at the 24-h time point. CHME3 cells were in-
fected with JEV (MOI 5) for 24 h and harvested for
RNA isolation. As seen in Figure 2B, IFN-β mRNA levels
were significantly increased with JEV infection over the
control (Figure 2B). These data confirm the activation of
an immune response in terms of IFN-β production
following JEV infection in CHME3 cells.
JEV induces phosphorylation of interferon regulatory
factor-3
In most of the viral infections, the production of type I
interferon is a key host immune response. This is medi-
ated by various interferon regulatory factors such as
IRF-3 (interferon regulatory factor-3) and IRF-7 (inter-
feron regulatory factor-7). JEV-infected CHME3 cells
showed significantly higher levels of active, phosphory-
lated IRF-3 as compared to controls (Figure 3A). An in-
crease in p-IRF3 levels as seen by Western blotting
corresponds with the production of IFN-β (Figure 2),
observed at 24 h of JEV infection. Alternatively, IRF-7
phosphorylation was not affected in CHME3 cells in-
fected with JEV at MOI 5 for 24 h (Figure 3B).ciferase activity in human microglial cells. (A) CHME3 cells were
smid and infected with JEV at MOI 5 for 6, 12, 24 and 36 h. Luciferase
periments. (B) CHME3 cells were infected with JEV at MOI 5 for 24 h
ld change of the IFN-β1 mRNA level for three independent
om control, #p from 6 h, $p from 12 h).
Figure 3 JEV induces phosphorylated IRF-3 levels in human microglial cells. (A) CHME3 cells were either un-infected or infected with JEV at
MOI 5 for 24 h. Cell lysates were resolved on SDS-PAGE and probed with anti-p-IRF3 antibody, anti-p-IRF7, anti-IRF3 and anti-IRF7 antibodies, and
anti-β-tubulin antibody (loading control) by Western blotting. Representatives of three independent experiments are shown. (B) Densitometry
analyses of Western blot experiments were performed with normalizing p-IRF-3 and p-IRF-7 against their respective controls IRF-3 and IRF-7 as
well as against β-tubulin (***p <0.001, *p < 0.05 from control).
Manocha et al. Journal of Neuroinflammation 2014, 11:24 Page 6 of 12
http://www.jneuroinflammation.com/content/11/1/24JEV infection induces the expression of TRIM21 in human
microglial cells in a time-dependent manner
TRIM21, an autoantigen, is known to interact with IRF-
3, IRF-7 and IRF-8. Because of these interactions, it is a
key regulator of the type I interferon immune response.
TRIM21 is an E3 ubiquitin ligase that can interact with
and ubiquitinate its target molecules. Since JEV induces
p-IRF3 and IFN-β expression in human microglial cells
(CHME3), we tried to understand the role of TRIM pro-
teins, specifically TRIM21, in regulation of the type I
interferon pathway. In order to identify the involvement
of TRIM21 in JEV-infected CHME3 cells, we first deter-
mined the effect of JEV on the TRIM21 level in the cells.
CHME3 cells were infected with JEV (MOI 5) and har-
vested at various time points. TRIM21 codes for 52 KDa
RoSSA protein and Western blotting against the anti-
body for this protein (from hereon called TRIM21 pro-
tein) showed a time-dependent increase in TRIM21
levels for up to 36 h (Figure 4A). CHME3 cells infected
with JEV at MOI 5 for 24 h showed increased mRNAlevels for the TRIM21 gene (Figure 4B). Additionally, a
time-course experiment for JEV infection was performed
in HeLa cells to observe the expression of IFN-β as well
as TRIM21. Although IFN-β levels increased upon JEV
infection after 12 h, there was no change in TRIM21
levels in HeLa cells following JEV infection at any given
time point (Additional file 1: Figure S1A & B). This sug-
gested that the role of TRIM21 during JEV infection is
specific to human microglial cells.
TRIM21 overexpression attenuates JEV-mediated
upregulation of p-IRF3
Since TRIM21 interacts with IRF-3 directly, it has an
important regulatory role in the immune response. We
hypothesized that the upregulation of TRIM21 in JEV-
infected cells could be a mechanism toward counteracting
the production of type I interferons and/or an antiviral re-
sponse towards the virus infection. The exogenous TRIM21
may further enhance this counteraction and may attenuate
the effects in JEV-infected CHME3 cells in terms of
Figure 4 JEV induces TRIM21 protein levels in human microglial cells in a time-dependent manner. (A) CHME3 cells were either un-infected
or infected with JEV at MOI 5 for 6, 12, 24 and 36 h. Cell lysates were resolved on SDS-PAGE and probed with anti-TRIM21 antibody and anti-β-
tubulin antibody (loading control) by Western blotting. A representation of three independent experiments is shown along with densitometry
analysis with normalization of TRIM21 against β-tubulin, averaging and plotting. (B) CHME3 cells were infected with JEV for 24 h (MOI 5). Total RNA
was isolated from harvested cells. cDNA prepared by reverse transcription of control and infected samples was used as a template for qPCR against
primers for TRIM21 gene. Average fold change in the TRIM21 mRNA level from three independent experiments is plotted and shown (*p < 0.05,
**p < 0.01, ***p < 0.001 from control, #p from 6 h, $p from 12 h).
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pressed in CHME3 cells via plasmid transfection in
order to observe the effect of TRIM21 on the IRF-3 level
and JEV-mediated IRF-3 phosphorylation. The presence of
exogenous TRIM21 and TRIM 21 (ΔRING) in CHME3
cells was observed through Western blotting studies. As
shown in Figure 1A, TRIM21-transfected CHME3 cells
showed TRIM21 antibody reactivity by Western blotting
at 52 KDa, while cells transfected with TRIM 21 (ΔRING)
showed a band slightly lower than the 52 KDa mark. Cells
transfected with TRIM21 were infected by JEV after 24 h
of transfection, and lysates were probed for phosphory-
lated IRF3 levels by Western blotting. As expected, JEV
infection increased p-IRF3 levels in CHME3 cells as com-
pared to control (GFP vector-transfected controls). How-
ever, overexpression of TRIM21 prior to infection resulted
in a reduction of p-IRF3 levels post infection compared to
the CHME3 cells only infected with JEV without TRIM21
transfection (Figure 1B). This suggests that TRIM21 could
result in attenuation of JEV-mediated IRF-3 activation.
Therefore, TRIM21 had an inhibitory effect on IRF3 acti-
vation. The total IRF-3 level was unaltered in the CHME3
cells infected with JEV, but TRIM21 overexpression re-
duced the level of total IRF3. This suggests that TRIM21
directly inhibits unphosphorylated IRF-3 in the presence
or absence of JEV infection. This was further validated by
using TRIM21 (ΔRING) plasmid in transfection studies.
TRIM21 lacking the RING domain had no effect on theIRF3 level (Figure 1A,B). As a result, p-IRF3 levels were
also not attenuated in TRIM21 (ΔRING)-transfected
CHME3 cells following JEV infection (Figure 1B).
TRIM21 overexpression represses JEV-mediated elevation
in IFN-β levels
We observed an increased production of IFN-β in JEV-
infected CHME3 cells (Figure 2). Since TRIM21 trans-
fection attenuates the activation of IRF3, it can be
expected that TRIM21 leads to downstream inhibitory
effects as well. Hence, in order to understand the role of
TRIM21 on IFN-β production, we checked the levels of
IFN-β mRNA as well as IFN-β luciferase activity in
TRIM21-overexpressed CHME3 cells. Human IFN-β is
encoded by the IFN-β1 gene. CHME3 cells were trans-
fected with TRIM21 plasmid and infected with JEV 24 h
post transfection. The CHME3 cells were harvested and
RNA isolated for real-time quantification of the IFN-β1
mRNA level using the primers mentioned in Table 1,
and fold change in the mRNA level was determined by
normalizing the IFN-β1 Ct values against those of β-
actin. As observed in Figure 2B, we found an increased
expression of IFN-β1 at mRNA levels in JEV-infected
CHME3 cells as compared to vector controls (Figure 1C).
However, we observed the reduction in IFN-β1 levels in
JEV-infected TRIM21-transfected CHME3 cells in accord-
ance with IRF-3 activation compared to controls. CHME3
cells transfected with truncated TRIM21 lacking the RING
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similar trend was observed with IFN-β luciferase activity.
Cells were transfected with IFN-β-luciferase promoter and
β-gal with or without TRIM21 plasmid followed by JEV
infection. Luciferase activity was measured 48 h post
transfection. JEV-infected cells showed significantly higher
luciferase activity of IFN-β-luciferase promoter; however,
transfection of TRIM21 before JEV infection attenuated
JEV-mediated luciferase activity (Figure 1D). This observa-
tion suggests that TRIM21 has an inhibitory role in
interferon-β production after JEV infection.
TRIM21 silencing facilitates JEV-mediated upregulation of
the p-IRF3 level in CHME3 cells
To further confirm the inhibitory role of TRIM21 on IFN-
β production, siRNA against TRIM21 was used to knock
down the expression of TRIM21 in CHME3 cells. SilencingFigure 5 TRIM21 knockdown facilitates JEV-mediated IRF3 activation
transfected with negative control RNA (NC) or transfected with 10nM siRNA
probed with anti-TRIM21 antibody and anti-β-tubulin antibody by Western
non-transfected (C), transfected with negative control RNA (NC) or with TRI
resolved on SDS-PAGE and probed with anti-p-IRF3 antibody, anti-IRF3 and
representative of three independent experiments is shown. Densitometry a
p-IRF-3 and p-IRF-3 against β-tubulin. (C) Real-time PCR for IFN-β1 for siRNA
was performed and averaged for three independent sets of experiments. (D
TRIM21 and infected with JEV along with respective controls was performe
and plotted (**p < 0.01, ***p < 0.001 from control).of TRIM21 was performed by using commercially available
siRNA duplexes against TRIM21 that resulted in >70%
knockdown of TRIM21 as shown in Figure 5A. Since JEV
infection stimulated IRF3 activation and phosphorylation,
this phenomenon was checked following TRIM21 silen-
cing. JEV-infected CHME3 cells showed increased phos-
phorylation of IRF3 as compared to controls; however,
silencing of TRIM21 prior to infection further enhanced
the phosphorylation and activation of IRF3 (Figure 5B).
This further confirmed the inhibitory role of dysregulated
endogenous TRIM21 during JEV infection in human
microglial cells.
TRIM21 silencing upregulates the JEV-mediated increase
in IFN-β level
Further downstream from IRF3 activation, the expres-
sion level of IFN-β was checked in order to confirm theand upregulation of the IFN-β level. (A) Cells were either
against TRIM21 for 48 h. Cell lysates were resolved on SDS-PAGE and
blotting. A representative image is shown. (B) Cells were either
M21 siRNA for 24 h followed by JEV infection for 24 h. Cell lysates were
anti-β-tubulin antibodies (loading control) by Western blotting. A
nalyses of Western blot experiments were performed with normalizing
-transfected and JEV-infected cells along with the respective controls
) Luciferase assay for IFN-β for cells transfected with siRNA against
d. Luciferase activity normalized against β-gal activity was averaged
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interferon in case of JEV infection. Again, corresponding
to the IRF3 activation, JEV-infection resulted in an add-
itional increase in the IFN-β mRNA level as well as IFN-
β-luciferase activity in CHME3 cells, where TRIM21 was
silenced prior to the JEV infection (Figure 5C,D).
Discussion
This study reports that JEV infection induces the expres-
sion of TRIM21 in human microglial cells. Exogenous
overexpression of TRIM21 attenuates JEV-mediated acti-
vation and phosphorylation of IRF3 as well as expression
of IFN-β levels. In addition, TRIM21 silencing leads to
facilitation of JEV-mediated IRF3 phosphorylation and
downstream induction of IFN-β.
We demonstrated that JEV induces IRF3 activation at
24 h of JEV infection. However, levels of phosphorylated
IRF7 are not significantly different in the infected cells
as compared to control after 24 h. IRF7 has been re-
ported to become activated only during the early phases
of JEV infection, and the levels of p-IRF7 are not ele-
vated during late phases of JEV infection [30]. Therefore,
our study was focused on understanding the role of
TRIM protein during JEV infection in the type I inter-
feron pathway in terms of IRF3 activation as well as its
effect on the expression of IFN-β. The production of
IFN-β by JEV is known to occur through the RIG-1-
mediated pathway [3]. However, the role of TRIM
proteins in modulating the immune response in JEV in-
fection had not yet been reported.
TRIM proteins are known to act as antiviral mole-
cules because of their specific actions against specific
viruses, as well as regulators of immune signaling path-
way [15,25,31,32]. TRIM79α is reported to restrict viral
replication of the tick-borne encephalitis virus (TBEV),
but not other flaviviruses, such as West Nile virus [33].
TRIM56 has been reported to restrict bovine viral diarrhea
virus replication in vitro [34]. The antiviral activity of
TRIM21 has been reported to be through the antibody-
mediated pathway [28,35]. It targets the virus toward pro-
teasomal degradation by ubiquitination. Vaysburd et al.
[28] showed that sensing of antibody-coated pathogens
through TRIM21 increased in the case of nonenveloped
DNA viruses, RNA viruses and intracellular bacterial in-
fections [28,35]. While TRIM21 acts as an Fc receptor in
sensing the antibody-coated viruses, the modulation of the
immune signaling pathway by TRIM21 is dependent on
the targeting of interferon regulatory factors via ubiquiti-
nation. We observed that JEV increases the expression of
TRIM21 in CHME3 cells as a negative regulator of the
type I interferon-mediated pathway. Two schools of
thoughts exist regarding the action of TRIM21 in modu-
lating the interferon pathway [25-27,36-38]. One suggests
that TRIM21 promotes degradation of IRF-3 and IRF-7,thereby limiting type I interferon production. Our study
supports the same findings as we observed the degrad-
ation of IRF-3 by TRIM21 in CHME3 cells; hence, the
availability of less phosphorylated forms of IRF-3 ultim-
ately leads to reduced expression of IFN-β [26,37]. Since
there was no change in IRF3 levels and subsequent IFN-β
levels upon TRIM21 (ΔRING) transfection, it suggested
that the E3 ligase activity of TRIM21 may be responsible
for the regulation of IRF3 expression. Our finding sup-
ports the those of Higgs et al. [26] in which they showed
that both the RING domain and the SPRY domain are
equally required to regulate the expression of IRF3 by the
interaction and proteasomal degradation of IRF3 [26].
Hence, the absence of any one of the domains is sufficient
to validate the role of TRIM21 in IRF3 and IFN-β regula-
tion during JEV infection. The other school of thought
supports the stabilization of IRF3 expression through a
TRIM21-mediated pathway. This has been reported in the
case of Sendai virus infection, where TRIM21 acts as a
positive regulator of the IRF3 pathway during viral infec-
tion [27]. This functional variability could be attributed to
being dependent on the type of viral infection, the dur-
ation of infection and the upstream signaling pathway.
Apart from RNA virus recognition, TRIM21 is also able to
modulate DNA virus infections. TRIM21 has been shown
to interact with DDX41, a cytosolic DNA sensor that trig-
gers type I IFN responses [39]. TRIM21 causes ubiquitina-
tion of DDX41, leading to a lesser production of IFN-β. A
number of other TRIM proteins are also involved in
modulating the inflammatory signaling pathways. TRIM30
(TRIM79α) is reported to be involved in lysosomal deg-
radation of TAK1 binding protein 2 (TAB2) and TAK1
binding protein 3 (TAB3) downstream of the TLR4 path-
way, leading to the inhibition of NF-ҡB induction during
LPS stimulation [40]. Like TRIM21, TRIM27 is also known
to target IKKs, thereby negatively regulating PRR pathways
[41]. TRIM5α is also known to negatively regulate NF-ҡB
and mitogen-activated protein kinase (MAPK) signaling
pathways by targeting TGF-β-activated kinase 1 (TAK1),
and these activities are known to be uncoupled from the
retroviral capsid recognition [42,43]. TAK1 has also been
reported to be targeted by TRIM8 [44]. TRIM5α has also
been reported to positively regulate NF-ҡB signaling, AP-1
activation and expression of proinflammatory cytokines
[42]. TRIM23 acts as a cofactor in the regulation of NF-ҡB
activation in human cytomegalovirus infection [45]. There-
fore, the modulation of immune responses by TRIM pro-
teins can be highly specific based on the type of pathogens
and their derivatives.
The increased expression of TRIM21 during JEV infec-
tion and its inhibitory role act as a feedback mechanism to
attenuate the immune response (Figure 6). This is sup-
ported by the observation that the activation of IRF3 in
JEV infection is further enhanced by knockdown of
Figure 6 Model showing a plausible role of TRIM21 as a negative regulator of IRF3 activation and IFN-β production following JEV
infection in human microglial cells. JEV infection causes activation of the RIG-1 receptor, initiating a downstream signaling mechanism leading
to the activation of IRF-3. Phosphorylated IRF-3 dimerizes and translocates into the nucleus, where it leads to the transcription and production of
IFN-β. JEV infection also induces the TRIM21 protein, which negatively regulates IRF-3 phosphorylation, leading to reduced IFN-β production. The
upregulation of TRIM21 is proposed to be a feedback mechanism to inhibit the innate immune response in JEV infection.
Manocha et al. Journal of Neuroinflammation 2014, 11:24 Page 10 of 12
http://www.jneuroinflammation.com/content/11/1/24TRIM21 in CHME3 cells prior to infection. Consequently,
the IFN-β level was also increased in JEV-infected TRIM21
knocked-down cells. The expression of TRIM21 has also
been reported to be induced by IFN-α and IFN-β via the
IRF-mediated pathway [46]. Other TRIM proteins, such as
TRIM5α and TRIM19, can also be altered by type I IFNs
[47-51]. Two independent studies have reported the ex-
pression of many TRIM proteins following type I inter-
feron stimulation in mouse macrophages, dendritic cells,
primary human-monocyte-derived macrophages and hu-
man primary lymphocytes [47,48]. Zhao et al. [52] re-
ported that TRIM 38 acts as a negative feedback regulator
of NF-ҡB signaling in TLR agonist-treated macrophages
[52]. This evidence along with our observations suggests
the involvement of a possible feedback mechanism for the
expression of TRIM proteins by interferon-mediated re-
sponses during viral infections. In summary, we suggest
that JEV infection in human microglial cells triggers an in-
nate immune response in terms of IFN-β production. The
expression of IFN-β in turn is suppressed by increased ex-
pression of TRIM21 during JEV infection in human
microglial cells. Probably JEV utilizes this strategy to sup-
press the type I interferon response as a part of an im-
mune evasion mechanism. However, further studies are
required to understand the involvement of other TRIM
proteins as an antiviral factor against other flaviviruses in
order to understand the mechanisms of pathogenesis as
well as to develop therapeutic tools.Conclusion
JEV infection in human microglial cells induced the ex-
pression of TRIM21 protein. Exogenous expression of
TRIM21 in human microglial cells resulted in attenuation
of JEV-mediated effects in terms of activation of interferon
regulatory factor-3 and production of interferon-β. Further
knockdown of TRIM21 enhances the JEV-mediated IRF-3
activation and IFN-β production. Although upstream
mechanisms of JEV-mediated IRF-3 phosphorylation are
known, this study provides the first evidence of the in-
volvement of TRIM21 protein in negatively regulating the
innate immune response by targeting IRF-3-mediated
IFN-β production during JEV infection. JEV could exploit
this strategy to suppress the type I interferon response
during the early course of infection.
Additional file
Additional file 1: Figure S1. JEV infection does not affect TRIM21
protein levels in HeLa cells. HeLa cells were infected with JEV at MOI 5
and harvested at different time intervals of 6, 12, 24 and 36 h. Cells were
either lysed for Western blotting against anti- TRIM21 antibody (A) or
lysed using reporter lysis buffer for IFN-β luciferase assay (B). All
experiments were performed as sets of three independent experiments
and data averaged and plotted as mean ± SEM (*p < 0.05, **p < 0.01,
***p < 0.001 from control, #p from 6 h, $p from 12 h).
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